Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
- PMID: 28843224
- PMCID: PMC5697462
- DOI: 10.22034/APJCP.2017.18.8.2073
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
Abstract
Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed our database and enrolled patients with MPM who received platinum containing chemotherapy (2012-2014). Clinico-pathological and laboratory data were retrieved and Cox and logistic regression multivariate analyses (MVA) were respectively used to identify predictors of survival and response to chemotherapy. Comparison of good vs poor performance status (PS≥II) was accomplished using the Chi (X2) test. Kaplan–Meier survival curves were also obtained and propensity-score matching was performed for survival comparison. Results: Among 114 patients listed during the study period, 82 had good PS=0-I (median age 45years, 43 men, 30 smokers, median weight=77Kg, pretreatment haemoglobin (Hb) level=12g/dL, platelet count=372,000/μL, leukocytes=9,700/μL, neutrophils=6,100/μL, lymphocytes=1,890/μL and neutrophil/lymphocyte ratio (NLR)=3.60 ). Some 65 had asbestosis, 23 had chronic disease, 55 (67.1%) were responders to platinum containing first line chemotherapy. A total of 49 (59.8%) had epithelial MPM. Median-OS and PFS in good PS cases were 17 and 9 months, respectively, as compared to 16 and 8 months for the poor PS group. After matching, better OS was observed among good PS vs poor PS patients (p=0.024) but there was no PFS difference (p=0.176). Significant decrease in PFS was observed among those with advanced nodal N disease (median PFS in N0 and N+ was 10 and 5 months, respectively), non-responders (p=0.012), NLR (p=0.026) and those with an epithelial pathology (p=0.062). MVA demonstrated that advanced (N) status (p=0.015), being a non-responder (p<0.001), NLR (p=0.015) and smoking (p=0.07) adversely affected the prognosis. The only predictor of response was absence of metastasis (M0; p=0.04). Conclusions: In addition to previously recognized factors, like nodal status, response, smoking and NLR, better median survival was evident in our patients with a good PS. Early detection before development of metastasis warrants greater focus to allow better responses to be obtained.
Keywords: mpm; perdictors; response; performance.
Creative Commons Attribution License
Figures
Similar articles
-
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.Clin Lung Cancer. 2013 Jan;14(1):70-7. doi: 10.1016/j.cllc.2012.03.011. Epub 2012 Jun 1. Clin Lung Cancer. 2013. PMID: 22658812
-
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.J Thorac Oncol. 2011 Nov;6(11):1923-9. doi: 10.1097/JTO.0b013e31822a3740. J Thorac Oncol. 2011. PMID: 22011651
-
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.Oncotarget. 2017 Feb 16;8(34):57460-57469. doi: 10.18632/oncotarget.15404. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915685 Free PMC article.
-
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.Br J Cancer. 2013 Oct 1;109(7):1813-20. doi: 10.1038/bjc.2013.504. Epub 2013 Aug 27. Br J Cancer. 2013. PMID: 23982605 Free PMC article.
-
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.J Thorac Oncol. 2015 Nov;10(11):1634-41. doi: 10.1097/JTO.0000000000000661. J Thorac Oncol. 2015. PMID: 26317916 Review.
Cited by
-
Thoracic surgery in Egypt.J Thorac Dis. 2022 Apr;14(4):1282-1295. doi: 10.21037/jtd-21-723. J Thorac Dis. 2022. PMID: 35572880 Free PMC article. Review.
-
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma.JAMA Netw Open. 2022 Mar 1;5(3):e221490. doi: 10.1001/jamanetworkopen.2022.1490. JAMA Netw Open. 2022. PMID: 35262715 Free PMC article.
-
Air pollution and survival in patients with malignant mesothelioma and asbestos-related lung cancer: a follow-up study of 1591 patients in South Korea.Environ Health. 2024 Jun 10;23(1):56. doi: 10.1186/s12940-024-01094-y. Environ Health. 2024. PMID: 38858710 Free PMC article.
-
The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis.Medicina (Kaunas). 2025 Jan 16;61(1):144. doi: 10.3390/medicina61010144. Medicina (Kaunas). 2025. PMID: 39859125 Free PMC article.
-
Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.J Thorac Dis. 2019 Apr;11(4):1456-1464. doi: 10.21037/jtd.2019.03.38. J Thorac Dis. 2019. PMID: 31179088 Free PMC article.
References
-
- Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007;45:379–87. - PubMed
-
- Blayney JK, Ceresoli GL, Castagneto B, et al. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer. 2012;48:2983–92. - PubMed
-
- Borasio P, Berruti A, Billé A, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:307–13. - PubMed
-
- Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol. 1998;16:145–52. - PubMed